SELECTIVE ESTROGEN RECEPTOR DEGRADERS PORTFOLIO INVESTMENT
Genentech places large bet on SERDs in a potential $1.725B Seragon buy
By Marie Powers
Thursday, July 3, 2014
Roche AG unit Genentech is plunking down $725 million in cash, plus contingent milestone-based payments of up to $1 billion, to purchase Seragon Pharmaceuticals Inc. and its portfolio of oral selective estrogen receptor degraders (SERDs), designed to treat hormone receptor-positive breast cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.